TB R&D Weekly Update: Tailoring TB Treatment Based on Host Genotype?

Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King M, Serhan CN, Ramakrishnan L. Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections. Cell. 2012 Feb 3; 148(3):434-446.

This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes and responses. We interviewed Dr. Lalita Ramakrishnan and members of her team about efflux pumps and their role in development of drug resistance. The current article explores the genetics involved in the inflammatory response during TB infection, specifically a gene that effects the overproduction or underproduction of the inflammatory mediator TNF-alpha, and using this information to potentially factor into the TB treatment provided to a patient.


Susceptibility to tuberculosis is historically ascribed to an inadequate immune response that fails to control infecting mycobacteria. In zebrafish, we find that susceptibility to Mycobacterium marinum can result from either inadequate or excessive acute inflammation. Modulation of the leukotriene A4 hydrolase (LTA4H) locus, which controls the balance of pro- and anti-inflammatory eicosanoids, reveals two distinct molecular routes to mycobacterial susceptibility converging on dysregulated TNF levels: inadequate inflammation causedby excess lipoxins and hyperinflammation driven by excess leukotriene B4. We identify therapies that specifically target each of these extremes. In humans, we identify a single nucleotide polymorphism in the LTA4H promoter that regulates its transcriptional activity. In tuberculous meningitis, the polymorphism is associated with inflammatory cell recruitment, patient survival and response to adjunctive anti-inflammatory therapy. Together, our findings suggest that host-directed therapies tailored to patient LTA4H genotypes may counter detrimental effects of either extreme of inflammation.

Additional TB R&D News:

Innate Immunity to TB: A Druggable Balancing Act (Cell)

‘Goldilocks’ gene could determine best treatment for tuberculosis patients

Identifying co-targets to fight drug resistance based on a random walk model

Multidrug-Resistant Tuberculosis – Update

Inaccurate TB blood tests commonplace in many TB high-burden countries

NIAID announces funding ops for HIV Clinical Trial Networks, including TB and Hepatitis

More News
23 Aug 2022
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...